Church & Dwight Co., Inc. $CHD Shares Bought by Bessemer Group Inc.

Bessemer Group Inc. grew its holdings in shares of Church & Dwight Co., Inc. (NYSE:CHD) by 56.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 4,330 shares of the company’s stock after acquiring an additional 1,558 shares during the quarter. Bessemer Group Inc.’s holdings in Church & Dwight were worth $416,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Wayfinding Financial LLC acquired a new position in Church & Dwight during the 1st quarter worth $40,000. Chilton Capital Management LLC boosted its position in Church & Dwight by 90.9% during the 1st quarter. Chilton Capital Management LLC now owns 420 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares during the period. Motco acquired a new position in Church & Dwight during the 1st quarter worth $46,000. Opal Wealth Advisors LLC acquired a new position in Church & Dwight during the 2nd quarter worth $45,000. Finally, Hexagon Capital Partners LLC boosted its position in Church & Dwight by 38.0% during the 1st quarter. Hexagon Capital Partners LLC now owns 472 shares of the company’s stock worth $52,000 after acquiring an additional 130 shares during the period. Institutional investors and hedge funds own 86.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CHD. JPMorgan Chase & Co. reduced their price target on Church & Dwight from $97.00 to $92.00 and set an “underweight” rating for the company in a research report on Monday, August 4th. Oppenheimer set a $100.00 price objective on Church & Dwight and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Barclays dropped their price objective on Church & Dwight from $84.00 to $83.00 and set an “underweight” rating on the stock in a research note on Monday, August 4th. Redburn Atlantic downgraded Church & Dwight from a “hold” rating to a “strong sell” rating in a research note on Monday, July 14th. Finally, Bank of America dropped their price objective on Church & Dwight from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, Church & Dwight has a consensus rating of “Hold” and an average target price of $100.00.

Insider Transactions at Church & Dwight

In other Church & Dwight news, EVP Michael Read purchased 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 5th. The shares were purchased at an average cost of $91.27 per share, with a total value of $182,540.00. Following the completion of the transaction, the executive vice president owned 7,505 shares of the company’s stock, valued at approximately $684,981.35. This represents a 36.33% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Lee B. Mcchesney purchased 5,409 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $91.38 per share, for a total transaction of $494,274.42. Following the completion of the transaction, the executive vice president directly owned 5,409 shares of the company’s stock, valued at $494,274.42. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 12,879 shares of company stock valued at $1,177,702 over the last three months. Company insiders own 2.00% of the company’s stock.

Church & Dwight Stock Up 7.2%

Shares of Church & Dwight stock opened at $87.66 on Monday. The stock’s fifty day moving average is $89.39 and its 200-day moving average is $93.95. The firm has a market capitalization of $21.36 billion, a PE ratio of 41.35, a price-to-earnings-growth ratio of 3.52 and a beta of 0.43. The company has a quick ratio of 1.33, a current ratio of 1.84 and a debt-to-equity ratio of 0.50. Church & Dwight Co., Inc. has a 12-month low of $81.33 and a 12-month high of $116.46.

Church & Dwight (NYSE:CHD) last announced its earnings results on Friday, October 31st. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.08. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.54 billion. Church & Dwight had a return on equity of 19.27% and a net margin of 8.66%.Church & Dwight’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.79 earnings per share. Church & Dwight has set its Q4 2025 guidance at 0.830-0.83 EPS. FY 2025 guidance at 3.490-3.49 EPS. Equities analysts anticipate that Church & Dwight Co., Inc. will post 3.7 earnings per share for the current year.

Church & Dwight Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be given a dividend of $0.295 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.18 dividend on an annualized basis and a dividend yield of 1.3%. Church & Dwight’s payout ratio is 37.11%.

Church & Dwight Profile

Church & Dwight Co, Inc engages in the development, manufacture, and marketing of household, personal care, and specialty products. It operates through the following segments: Consumer Domestic, Consumer International, Specialty Products Division (SPD), and Corporate. The Consumer Domestic segment offers household products, such as laundry detergents, fabric softener sheets, cat litter, household cleaning products, and personal care products including antiperspirants, oral care products, depilatories, reproductive health products, oral analgesics, nasal saline moisturizers, and dietary supplements.